March 28th 2023
Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.
Neoadjuvant Durvalumab Plus Tremelimumab Combo Elicits Response in Advanced Ovarian Cancer
April 14th 2022Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.
Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 14th 2022Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.
Individualized Starting Dose of Maintenance Niraparib Increases PFS vs Placebo in Ovarian Cancer
March 20th 2022The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.
Early Activity of Neoadjuvant Niraparib in HRD+ Ovarian Cancer Reported in NANT Trial
March 19th 2022Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.